Rufloxacin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rufloxacin
Accession Number
DB13772
Type
Small Molecule
Groups
Experimental
Description

Rufloxacin is a quinolone antibiotic. [1]

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Rufloxacin hydrochloride1643374N6L106017-08-7LPQOADBMXVRBNX-UHFFFAOYSA-N
Categories
UNII
Y521XM2900
CAS number
101363-10-4
Weight
Average: 363.407
Monoisotopic: 363.105290352
Chemical Formula
C17H18FN3O3S
InChI Key
NJCJBUHJQLFDSW-UHFFFAOYSA-N
InChI
InChI=1S/C17H18FN3O3S/c1-19-2-4-20(5-3-19)14-12(18)8-10-13-16(14)25-7-6-21(13)9-11(15(10)22)17(23)24/h8-9H,2-7H2,1H3,(H,23,24)
IUPAC Name
7-fluoro-6-(4-methylpiperazin-1-yl)-10-oxo-4-thia-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid
SMILES
CN1CCN(CC1)C1=C(F)C=C2C(=O)C(=CN3CCSC1=C23)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcarboseRufloxacin may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AlbiglutideRufloxacin may increase the hypoglycemic activities of Albiglutide.Approved
AlogliptinRufloxacin may increase the hypoglycemic activities of Alogliptin.Approved
BromocriptineRufloxacin may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
CanagliflozinRufloxacin may increase the hypoglycemic activities of Canagliflozin.Approved
ChlorpropamideRufloxacin may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
DapagliflozinRufloxacin may increase the hypoglycemic activities of Dapagliflozin.Approved
DelamanidRufloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DisopyramideRufloxacin may increase the hypoglycemic activities of Disopyramide.Approved
DulaglutideRufloxacin may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
EmpagliflozinRufloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
ExenatideRufloxacin may increase the hypoglycemic activities of Exenatide.Approved, Investigational
GliclazideRufloxacin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideRufloxacin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideRufloxacin may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburideRufloxacin may increase the hypoglycemic activities of Glyburide.Approved
Insulin AspartRufloxacin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirRufloxacin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineRufloxacin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineRufloxacin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanRufloxacin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproRufloxacin may increase the hypoglycemic activities of Insulin Lispro.Approved
LiraglutideRufloxacin may increase the hypoglycemic activities of Liraglutide.Approved
MecaserminRufloxacin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MetforminRufloxacin may increase the hypoglycemic activities of Metformin.Approved
MifepristoneRufloxacin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolRufloxacin may increase the hypoglycemic activities of Miglitol.Approved
NateglinideRufloxacin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
PentamidineRufloxacin may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PioglitazoneRufloxacin may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PramlintideRufloxacin may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
QuinineRufloxacin may increase the hypoglycemic activities of Quinine.Approved
RepaglinideRufloxacin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RosiglitazoneRufloxacin may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SaxagliptinRufloxacin may increase the hypoglycemic activities of Saxagliptin.Approved
SitagliptinRufloxacin may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SulfadiazineRufloxacin may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleRufloxacin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleRufloxacin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibRufloxacin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TolazamideRufloxacin may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamideRufloxacin may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Rafalsky V, Andreeva I, Rjabkova E: Quinolones for uncomplicated acute cystitis in women. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD003597. doi: 10.1002/14651858.CD003597.pub2. [PubMed:16856014]
External Links
Human Metabolome Database
HMDB0042009
KEGG Drug
D02474
KEGG Compound
C11240
ChemSpider
52489
ChEBI
8909
ChEMBL
CHEMBL295619
Wikipedia
Rufloxacin
ATC Codes
J01MA10 — Rufloxacin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.96 mg/mLALOGPS
logP0.13ALOGPS
logP0.83ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)5.4ChemAxon
pKa (Strongest Basic)6.09ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area64.09 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity97.02 m3·mol-1ChemAxon
Polarizability36.42 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-03k9-0169000000-0ec29246738d7398bc4e

Taxonomy

Description
This compound belongs to the class of organic compounds known as quinoline carboxylic acids. These are quinolines in which the quinoline ring system is substituted by a carboxyl group at one or more positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Quinoline carboxylic acids
Direct Parent
Quinoline carboxylic acids
Alternative Parents
Fluoroquinolones / N-arylpiperazines / Haloquinolines / Hydroquinolones / Aminoquinolines and derivatives / Benzothiazines / Hydroquinolines / Pyridinecarboxylic acids / Dialkylarylamines / N-methylpiperazines
show 16 more
Substituents
Quinoline-3-carboxylic acid / Fluoroquinolone / N-arylpiperazine / Aminoquinoline / Haloquinoline / Dihydroquinolone / Benzothiazine / Dihydroquinoline / Pyridine carboxylic acid / Pyridine carboxylic acid or derivatives
show 35 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
quinolines, quinolone antibiotic, fluoroquinolone antibiotic (CHEBI:8909)

Drug created on June 23, 2017 14:48 / Updated on June 02, 2018 09:52